



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert E. Reiter, et al.
Serial No.: 09/359,326
Filed: July 20, 1999
Docket: 30435.54US14
Title: **PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF**

RECEIVED
MAR 08 2001
TECH CENTER 1600/2900

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this paper or fee is being deposited with the United States Postal as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on February 26, 2001.

By: 
Name: Richelle Ann Domingo

35 N. Arroyo Parkway, Suite 60
Pasadena, California 91103
February 26, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8.
- ☒ Supplemental Information Disclosure Statement (37 C.F.R. §1.97 (c))
- ☒ Form 1449 (Supplemental Information Disclosure Statement)
- ☒ Exhibits 137 to 143
- ☒ A check is enclosed for the amount of \$180.00 to cover the fee.
- ☒ Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

35 N. Arroyo Parkway, Suite 60
Pasadena, California 91103
(626) 395-7801

By: 
Name: Sarah B. Adriano
Reg. No.: 34,470
Initials: SBA
Customer No. 26,941




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert E. Reiter, et al. **Examiner:** L. Helms
Serial No.: 09/359,326 **Group Art Unit:** 1643
Filed: July 20, 1999 **Docket No.:** 30435.54USI4
Title: PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on February 26, 2001.

By: 
Richelle Ann Domingo

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(c))

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

RECEIVED
MAR 08 2001
TECH CENTER 1600/2900

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- Cama, C., et al., "Molecular Staging of Prostate Cancer: II. A comparison of the Application of an Enhance Reverse Transcriptase Polymerase Chain Reaction Assay for Prostate Specific Antigen Versus Prostate Specific Membrane Antigen", *The Journal of Urology*, 1995, 153:1373-1378 (Exhibit 137)
- Horoszewicz, J. S., et al., "Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients", *Anticancer Research*, 1987, 7:927-936 (Exhibit 138)

- Israeli, R. S., et al., "Sensitive Nested Reverse Transcription Polymerase Chain Reaction Detection of Circulating Prostatic Tumor Cells: Comparison of Prostate-specific Membrane Antigen and Prostate-specific Antigen-based Assays", *Cancer Research*, 1994, 54:6306-6310 (Exhibit 139)
- Smith, M. R., et al., "Prostate-specific Antigen Messenger RNA is Expressed in Non-Prostate Cells: Implications for Detection of Micrometastases", *Cancer Research*, 1995, 55:2640-2644 (Exhibit 140)
- Sodee, D. B., et al., "Preliminary Imaging Results Using In-11 Labeled CYT-356 (Prostascint™) in the Detection of Recurrent Prostate Cancer", *Clinical Nuclear Medicine*, 1996, 21:759-767 (Exhibit 141)
- Wu, J. T., et al., "Assay for Prostate Specific Antigen (PSA): Problems and Possible Solutions", *Journal of Clinical Laboratory Analysis*, 1994, 8:51-62 (Exhibit 142)
- WO 98/51824 (Exhibit 143)

This statement should be considered because it is submitted before the mailing date of the final Office Action on the merits, under 37 C.F.R. § 1.97(c). In accordance with 37 C.F.R. §1.98(d), copies of Exhibits 1-136 are not provided as they have been previously provided in applications, U.S. Serial No. 09/318,503, 09/251,835, 09/203,939 and 09/038,261. Copies of Exhibits 137-143 are provided.

Applicants include a check for the amount of \$180.00 under C.F.R. § 1.17(p). In accordance with 37 C.F.R. §1.98(d), copies of each document (Exhibits 137-143) listed on the enclosed Form 1449 are provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that the references have been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Robert E. Reiter, et al.
Serial No. 09/359,326
Filed: July 20, 1999
Page 4

A check in the amount of \$180.00 is enclosed to cover the fee. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-0306.

Respectfully submitted,

Sarah B. Adriano

Sarah B. Adriano
Registration No. 34,470
Attorney for Applicants
Mandel & Adriano
35 No. Arroyo Parkway, Suite 60
Pasadena, California 91103
(626) 395-7801
Customer No. 26,941